Table 4.

Pharmacokinetic parameters for the E31C analog and its PEGylated form after injection of a single dose into the vein tail of rats. As shown, EPO31-PEG has a lower elimination rate for unmodified protein that leads to a five-fold terminal half-life in plasma

Pharmacokinetic parameters	E31C analog	EPO31-PEG
Elimination rate constant (h−1)	0.096 ± 0.011	0.019 ± 0.003
Terminal half-life (h)	7.22 ± 1.3	36.47 ± 6.5
Area under the curve (0–∞) (ng.h/mL)	13205.22 ± 190.7	70238.03 ± 114.4
Clearance (mL/h/kg)	5.42 ± 0.82	0.46 ± 0.04

Note: The data are represented as mean ± standard deviation.